At a glance: GHK-Cu is a small copper-binding peptide that occurs naturally in human blood and declines with age. It is a popular skincare ingredient with 50 years of lab and animal research behind it, but human data are limited to small topical studies. No trial of injected GHK-Cu has been published, and injectable GHK-Cu currently has no FDA compounding classification.
What is GHK-Cu?
GHK-Cu is a tripeptide (three amino acids: glycine, histidine and lysine) bound to a copper ion. It occurs naturally in human plasma, saliva and urine. It was first identified in 1973 by researcher Loren Pickart, who found that a factor in young people's blood made older liver cells behave more like younger ones.
Blood levels fall with age, from roughly 200 ng/mL around age 20 to about 80 ng/mL by age 60, which is part of why it is marketed for anti-aging. In cosmetics it is often listed as copper tripeptide-1. Products are lab-made.
How does GHK-Cu work?
In cell and animal studies, GHK-Cu has been linked to:
- Collagen and elastin production: it stimulated skin cells to make collagen and other structural proteins
- Tissue remodeling: it influences enzymes that break down damaged tissue and their inhibitors, helping balance repair
- Wound healing and blood vessel growth in animal wound models
- Copper delivery: copper is needed by enzymes involved in skin structure and antioxidant defense
- Gene activity: computer analyses of gene databases suggest it may shift the activity of thousands of genes toward a "healthier" pattern, an intriguing but indirect finding
What the research shows so far
| Type of study | What was found | Strength of evidence |
|---|---|---|
| Cell studies (1970s onward) | Stimulated collagen production and tissue-repair activity in skin cells | Lab |
| Rat wound studies | Increased collagen in wounds; a topical gel shrank ischemic wounds by about 65% at day 13 vs about 46% with an inactive gel | Animal |
| Topical facial creams in women (8- to 12-week studies) | Improvements in fine lines, wrinkle depth, skin density and firmness vs control creams | Small human cosmetic studies, often industry-linked |
| Laser-resurfaced skin | No statistically significant objective difference; patients rated GHK-Cu more favorably | Small human study |
| Injected GHK-Cu | No published human trial | None |
A 2025 review described clinical studies of GHK-Cu as surprisingly scarce given its popularity.
Why it gets attention
- Anti-aging skincare: one of the best-known peptide ingredients in serums and creams
- Natural origin, with levels that decline with age
- Hair and scalp products, often alongside its synthetic cousin AHK-Cu
- Injectable and blend use: it is a main ingredient in GLOW and KLOW peptide blends, far beyond the evidence
How it is used
Most GHK-Cu is used topically in skin and hair products. It is also sold in oral, nasal and injectable forms. The skin barrier limits how much reaches deeper tissue from topical products; injection bypasses that barrier but has no human safety or effectiveness data. This page does not provide dosing or application guidance.
What about side effects?
Topical copper peptides are generally considered low risk, with mild irritation, redness or skin sensitivity the most common issues.
- Product interactions: using copper peptides in the same step as vitamin C, strong acids, retinoids or benzoyl peroxide can cause irritation or reduce effectiveness.
- Copper concerns: people with copper allergy or copper-metabolism disorders such as Wilson disease should avoid it, especially in non-topical forms.
- Injection risks: unknown long-term effects, possible immune reactions to impurities, and infection from non-sterile products. Growth-promoting effects are a theoretical concern for people with a history of cancer.
- Pregnancy and breastfeeding: not studied.
Regulatory status
- Topical GHK-Cu is a widely used cosmetic ingredient. For pharmacy compounding, non-injectable GHK-Cu is in FDA's Category 1 (under evaluation, with compounding allowed under enforcement discretion). It was briefly removed in April 2026 and restored on May 5, 2026, after the nominator clarified it meant to withdraw only the injectable form.
- Injectable GHK-Cu was removed from FDA's Category 2 safety-concern list in April 2026 but has no current classification, so it is not eligible for compounding. An FDA advisory committee review is expected before the end of February 2027.
- No form of GHK-Cu is an FDA-approved drug. Injectable products sold online as research peptides are unregulated and not intended for human use.
GHK-Cu vs AHK-Cu
| GHK-Cu | AHK-Cu | |
|---|---|---|
| Amino acids | Glycine-histidine-lysine + copper | Alanine-histidine-lysine + copper |
| Origin | Occurs naturally in human blood | Synthetic only |
| Main use | Skin, collagen and wound repair; also scalp | Hair and scalp |
| Research base | Decades of cell and animal research; small topical human studies | One 2007 lab study |
The bottom line
GHK-Cu has a longer research record than most peptides, and topical use in skincare appears reasonable and low risk, with small studies suggesting cosmetic benefits. But its human evidence is thin and largely cosmetic, and injected GHK-Cu has never been tested in a published trial and is not legally compoundable. Anyone considering it beyond a skincare product should talk with a dermatologist or clinician.
Frequently asked questions
What is GHK-Cu?
A small three-amino-acid peptide bound to copper. It occurs naturally in human blood, and levels fall with age. It is widely used in skincare products.
How is GHK-Cu taken?
Topical cream or serum (studied); injection (unstudied).
Is GHK-Cu FDA approved?
Allowed in cosmetics; not approved as a drug.
That means no regulator has reviewed its safety, effectiveness or manufacturing quality for this use.
What has research shown about GHK-Cu?
- Collagen production and skin appearance in topical studies.
- Wound healing in animal and lab studies.
- Gene activity linked to tissue repair in lab research.
What side effects have been reported?
- Topical: skin irritation; redness at strong concentrations
Serious or less common risks are listed in the Side Effects section above.
What is still unknown about its safety?
Most of it. GHK-Cu has not been through the trials that establish long-term safety in people, and products sold online are made by unregulated labs. Independent testing of online peptides has repeatedly found contents that do not match the label.
References
- Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. International Journal of Molecular Sciences. 2018;19(7):1987. View source
- Superpower: GLOW peptide blend research summary (GHK-Cu wound, laser-resurfacing and review citations). View source
- DJ Holt Law: Regulatory alert, FDA's April 2026 update on BPC-157 and GHK-Cu. View source
- Orrick: FDA announces removal of 12 peptides from Category 2 and schedules PCAC meetings (April 2026). View source
- Goodwin: FDA signals potentially evolving stance toward compounding of certain peptides (May 2026). View source